BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

284 related articles for article (PubMed ID: 32843547)

  • 1. Kaposi's Sarcoma-Associated Herpesvirus Drives a Super-Enhancer-Mediated Survival Gene Expression Program in Primary Effusion Lymphoma.
    Manzano M; Günther T; Ju H; Nicholas J; Bartom ET; Grundhoff A; Gottwein E
    mBio; 2020 Aug; 11(4):. PubMed ID: 32843547
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Global epigenomic analysis of KSHV-infected primary effusion lymphoma identifies functional
    Park A; Oh S; Jung KL; Choi UY; Lee HR; Rosenfeld MG; Jung JU
    Proc Natl Acad Sci U S A; 2020 Sep; 117(35):21618-21627. PubMed ID: 32817485
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Modulation of interferon regulatory factor 5 activities by the Kaposi sarcoma-associated herpesvirus-encoded viral interferon regulatory factor 3 contributes to immune evasion and lytic induction.
    Bi X; Yang L; Mancl ME; Barnes BJ
    J Interferon Cytokine Res; 2011 Apr; 31(4):373-82. PubMed ID: 21133648
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Cyclooxygenase-2-prostaglandin E2-eicosanoid receptor inflammatory axis: a key player in Kaposi's sarcoma-associated herpes virus associated malignancies.
    Paul AG; Chandran B; Sharma-Walia N
    Transl Res; 2013 Aug; 162(2):77-92. PubMed ID: 23567332
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Inhibition of primary effusion lymphoma engraftment in SCID mice by morpholino oligomers against early lytic genes of Kaposi's sarcoma-associated herpesvirus.
    Zhang YJ; Patel D; Nan Y; Fan S
    Antivir Ther; 2011; 16(5):657-66. PubMed ID: 21817187
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Druggable host gene dependencies in primary effusion lymphoma.
    Kuehnle N; Gottwein E
    Curr Opin Virol; 2022 Oct; 56():101270. PubMed ID: 36182745
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Mutual inhibition between Kaposi's sarcoma-associated herpesvirus and Epstein-Barr virus lytic replication initiators in dually-infected primary effusion lymphoma.
    Jiang Y; Xu D; Zhao Y; Zhang L
    PLoS One; 2008 Feb; 3(2):e1569. PubMed ID: 18253508
    [TBL] [Abstract][Full Text] [Related]  

  • 8. CADM1 is essential for KSHV-encoded vGPCR-and vFLIP-mediated chronic NF-κB activation.
    Hunte R; Alonso P; Thomas R; Bazile CA; Ramos JC; van der Weyden L; Dominguez-Bendala J; Khan WN; Shembade N
    PLoS Pathog; 2018 Apr; 14(4):e1006968. PubMed ID: 29698475
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Ago HITS-CLIP expands understanding of Kaposi's sarcoma-associated herpesvirus miRNA function in primary effusion lymphomas.
    Haecker I; Gay LA; Yang Y; Hu J; Morse AM; McIntyre LM; Renne R
    PLoS Pathog; 2012; 8(8):e1002884. PubMed ID: 22927820
    [TBL] [Abstract][Full Text] [Related]  

  • 10. CCAAT/enhancer-binding protein-alpha is induced during the early stages of Kaposi's sarcoma-associated herpesvirus (KSHV) lytic cycle reactivation and together with the KSHV replication and transcription activator (RTA) cooperatively stimulates the viral RTA, MTA, and PAN promoters.
    Wang SE; Wu FY; Yu Y; Hayward GS
    J Virol; 2003 Sep; 77(17):9590-612. PubMed ID: 12915572
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The viral interferon-regulatory factor-3 is required for the survival of KSHV-infected primary effusion lymphoma cells.
    Wies E; Mori Y; Hahn A; Kremmer E; Stürzl M; Fleckenstein B; Neipel F
    Blood; 2008 Jan; 111(1):320-7. PubMed ID: 17890449
    [TBL] [Abstract][Full Text] [Related]  

  • 12. X-box binding protein 1 induces the expression of the lytic cycle transactivator of Kaposi's sarcoma-associated herpesvirus but not Epstein-Barr virus in co-infected primary effusion lymphoma.
    Lai IY; Farrell PJ; Kellam P
    J Gen Virol; 2011 Feb; 92(Pt 2):421-31. PubMed ID: 20980528
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Kaposi's sarcoma-associated herpesvirus/human herpesvirus type 8-positive solid lymphomas: a tissue-based variant of primary effusion lymphoma.
    Carbone A; Gloghini A; Vaccher E; Cerri M; Gaidano G; Dalla-Favera R; Tirelli U
    J Mol Diagn; 2005 Feb; 7(1):17-27. PubMed ID: 15681470
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Kaposi's sarcoma-associated herpesvirus-encoded viral IRF3 modulates major histocompatibility complex class II (MHC-II) antigen presentation through MHC-II transactivator-dependent and -independent mechanisms: implications for oncogenesis.
    Zuo J; Hislop AD; Leung CS; Sabbah S; Rowe M
    J Virol; 2013 May; 87(10):5340-50. PubMed ID: 23449805
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The Kaposi's Sarcoma-associated Herpesvirus-encoded vIRF-3 Inhibits Cellular IRF-5.
    Wies E; Hahn AS; Schmidt K; Viebahn C; Rohland N; Lux A; Schellhorn T; Holzer A; Jung JU; Neipel F
    J Biol Chem; 2009 Mar; 284(13):8525-38. PubMed ID: 19129183
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Kaposi's sarcoma-associated herpesvirus LANA2 is a B-cell-specific latent viral protein that inhibits p53.
    Rivas C; Thlick AE; Parravicini C; Moore PS; Chang Y
    J Virol; 2001 Jan; 75(1):429-38. PubMed ID: 11119611
    [TBL] [Abstract][Full Text] [Related]  

  • 17. CRISPR/Cas9 ablating viral microRNA promotes lytic reactivation of Kaposi's sarcoma-associated herpesvirus.
    Liang Z; Qin Z; Riker AI; Xi Y
    Biochem Biophys Res Commun; 2020 Dec; 533(4):1400-1405. PubMed ID: 33092788
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Kaposi's sarcoma-associated herpesvirus (KSHV/HHV8): key aspects of epidemiology and pathogenesis.
    Viejo-Borbolla A; Schulz TF
    AIDS Rev; 2003; 5(4):222-9. PubMed ID: 15012001
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Direct activation of emmprin and associated pathogenesis by an oncogenic herpesvirus.
    Qin Z; Dai L; Slomiany MG; Toole BP; Parsons C
    Cancer Res; 2010 May; 70(10):3884-9. PubMed ID: 20406987
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Kaposi sarcoma-associated herpesvirus (KSHV): molecular biology and oncogenesis.
    Wen KW; Damania B
    Cancer Lett; 2010 Mar; 289(2):140-50. PubMed ID: 19651473
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.